SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
Rhea-AI Summary
SI-BONE (Nasdaq: SIBN) will present at the BofA Securities 2026 Healthcare Conference in Las Vegas on Tuesday, May 12, 2026. Management will host a fireside chat at 8:00 a.m. PT / 11:00 a.m. ET.
Live audio will be available via registration on the conference site and on the company Investors webpage; the webcast will be archived for at least 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – SIBN
In the May 1 session, SIBN gained 6.62%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.3% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will be hosting a fireside chat on Tuesday, May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/f3F578.cfm. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 180 peer reviewed publications.
For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.
SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.
Investor Contact
Saqib Iqbal
VP, FP&A and Investor Relations
investors@SI-BONE.com
